Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis
SUMMARY Cross‐reactive antibodies against heparan sulphate (HS) have been suggested to play a role in initiating renal disease in SLE. Recently, we found that HS‐reactivity is mediated by anti‐DNA antibodies complexed with DNA and histones. To evaluate the clinical significance of anti‐HS reactivity...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental immunology 1993-07, Vol.93 (1), p.34-38 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | 1 |
| container_start_page | 34 |
| container_title | Clinical and experimental immunology |
| container_volume | 93 |
| creator | KRAMERS, C. TERMAAT, R. M. BORG, E. J. BRUGGEN, M. C. J. KALLENBERG, C. G. M. BERDEN, J. H. M. |
| description | SUMMARY
Cross‐reactive antibodies against heparan sulphate (HS) have been suggested to play a role in initiating renal disease in SLE. Recently, we found that HS‐reactivity is mediated by anti‐DNA antibodies complexed with DNA and histones. To evaluate the clinical significance of anti‐HS reactivity, we studied prospectively a cohort of 72 consecutive SLE patients, of whom 22 experienced 40 exacerbations. In 20 of these exacerbations renal symptoms were present. In these 20 exacerbations significantly higher anti‐DNA (median 1:160) and anti‐HS (median 1:30) titres were detected compared with exacerbations without renal manifestations (median 1:60 for anti‐DNA and negative for anti‐HS). There were no correlations with other symptoms of SLE. Anti‐HS titres showed a significant correlation with anti‐DNA antibody titres (rs= 0·57, P < 0·05). Anti‐HS without anti‐DNA reactivity was never detected. Some SLE patients showed a high anti‐DNA titre without anti‐HS reactivity, suggesting that not all anti‐DNA antibodies are able to bind to histone/DNA complexes and thus to exhibit anti‐HS reactivity. Our findings indicate that anti‐HS reactivity is correlated with renal disease in SLE. |
| doi_str_mv | 10.1111/j.1365-2249.1993.tb06493.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1554757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16693374</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5354-ac278c7774233acb8d4475a7a56436e9990efb0b300c86da3bd7737d920e55333</originalsourceid><addsrcrecordid>eNqVUt2qEzEQXkQ51qOPIAQR0YvW7CbZ7CoKUqrnQMEL9TrMZqfdlOzPSbLndO98BF_CF_NJTGkpeiXmZhi-b76ZyTdJ8iylizS-17tFynIxzzJeLtKyZItQ0ZzHuL-XzM7Q_WRGKS3nZUr5w-SR97uY5nmeXSQXBYsEms2Sn1dm26Aj0AXz6_uPBgdw0BE_2qGBgMQh6GBuTZhIPTrTbYmffMDWaGLHYfQE3RQabCH0PmYvv6xXr0htPIJHgnvQ6CoIpu88uTOhiXodWNJCZzbowxF5S4DYPkoHdC0ZXO8HPDTFOBXYyRv_OHmwAevxySleJt8-rr4ur-brz5-ulx_Wcy2Y4HPQmSy0lJJnjIGuippzKUCCyDnLsSxLipuKVoxSXeQ1sKqWksm6zCgKwRi7TN4fdYexarHW2AUHVg3OtOAm1YNRfyOdadS2v1WpELGTjAIvTgKuvxnjhqo1XqO10GE_eiVFwQSVxT-JaZ6XjEkeiW-ORB3_xTvcnKdJqTpcg9qpg-XqYLk6XIM6XYPax-Knf-5zLj3ZH_HnJxy8BruJ1mvjzzRe5JIWNNLeHWl3xuL0HwOo5eqacfYbvlXX7w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16693374</pqid></control><display><type>article</type><title>Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>KRAMERS, C. ; TERMAAT, R. M. ; BORG, E. J. ; BRUGGEN, M. C. J. ; KALLENBERG, C. G. M. ; BERDEN, J. H. M.</creator><creatorcontrib>KRAMERS, C. ; TERMAAT, R. M. ; BORG, E. J. ; BRUGGEN, M. C. J. ; KALLENBERG, C. G. M. ; BERDEN, J. H. M.</creatorcontrib><description>SUMMARY
Cross‐reactive antibodies against heparan sulphate (HS) have been suggested to play a role in initiating renal disease in SLE. Recently, we found that HS‐reactivity is mediated by anti‐DNA antibodies complexed with DNA and histones. To evaluate the clinical significance of anti‐HS reactivity, we studied prospectively a cohort of 72 consecutive SLE patients, of whom 22 experienced 40 exacerbations. In 20 of these exacerbations renal symptoms were present. In these 20 exacerbations significantly higher anti‐DNA (median 1:160) and anti‐HS (median 1:30) titres were detected compared with exacerbations without renal manifestations (median 1:60 for anti‐DNA and negative for anti‐HS). There were no correlations with other symptoms of SLE. Anti‐HS titres showed a significant correlation with anti‐DNA antibody titres (rs= 0·57, P < 0·05). Anti‐HS without anti‐DNA reactivity was never detected. Some SLE patients showed a high anti‐DNA titre without anti‐HS reactivity, suggesting that not all anti‐DNA antibodies are able to bind to histone/DNA complexes and thus to exhibit anti‐HS reactivity. Our findings indicate that anti‐HS reactivity is correlated with renal disease in SLE.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1111/j.1365-2249.1993.tb06493.x</identifier><identifier>PMID: 8324902</identifier><identifier>CODEN: CEXIAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>antibodies ; Antibodies, Antinuclear - immunology ; anti‐DNA ; anti‐HS reactivity ; Biological and medical sciences ; Cross Reactions - immunology ; cross‐reactivity ; Enzyme-Linked Immunosorbent Assay ; erythematosus ; Female ; Heparitin Sulfate - immunology ; Humans ; Incidence ; Longitudinal Studies ; lupus ; Lupus Erythematosus, Systemic - diagnosis ; Lupus Erythematosus, Systemic - immunology ; Lupus Nephritis - diagnosis ; Lupus Nephritis - immunology ; Male ; Medical sciences ; nephritis ; prospective ; Prospective Studies ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; study ; systemic</subject><ispartof>Clinical and experimental immunology, 1993-07, Vol.93 (1), p.34-38</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5354-ac278c7774233acb8d4475a7a56436e9990efb0b300c86da3bd7737d920e55333</citedby><cites>FETCH-LOGICAL-c5354-ac278c7774233acb8d4475a7a56436e9990efb0b300c86da3bd7737d920e55333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1554757/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1554757/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4867080$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8324902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KRAMERS, C.</creatorcontrib><creatorcontrib>TERMAAT, R. M.</creatorcontrib><creatorcontrib>BORG, E. J.</creatorcontrib><creatorcontrib>BRUGGEN, M. C. J.</creatorcontrib><creatorcontrib>KALLENBERG, C. G. M.</creatorcontrib><creatorcontrib>BERDEN, J. H. M.</creatorcontrib><title>Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>SUMMARY
Cross‐reactive antibodies against heparan sulphate (HS) have been suggested to play a role in initiating renal disease in SLE. Recently, we found that HS‐reactivity is mediated by anti‐DNA antibodies complexed with DNA and histones. To evaluate the clinical significance of anti‐HS reactivity, we studied prospectively a cohort of 72 consecutive SLE patients, of whom 22 experienced 40 exacerbations. In 20 of these exacerbations renal symptoms were present. In these 20 exacerbations significantly higher anti‐DNA (median 1:160) and anti‐HS (median 1:30) titres were detected compared with exacerbations without renal manifestations (median 1:60 for anti‐DNA and negative for anti‐HS). There were no correlations with other symptoms of SLE. Anti‐HS titres showed a significant correlation with anti‐DNA antibody titres (rs= 0·57, P < 0·05). Anti‐HS without anti‐DNA reactivity was never detected. Some SLE patients showed a high anti‐DNA titre without anti‐HS reactivity, suggesting that not all anti‐DNA antibodies are able to bind to histone/DNA complexes and thus to exhibit anti‐HS reactivity. Our findings indicate that anti‐HS reactivity is correlated with renal disease in SLE.</description><subject>antibodies</subject><subject>Antibodies, Antinuclear - immunology</subject><subject>anti‐DNA</subject><subject>anti‐HS reactivity</subject><subject>Biological and medical sciences</subject><subject>Cross Reactions - immunology</subject><subject>cross‐reactivity</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>erythematosus</subject><subject>Female</subject><subject>Heparitin Sulfate - immunology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Longitudinal Studies</subject><subject>lupus</subject><subject>Lupus Erythematosus, Systemic - diagnosis</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Lupus Nephritis - diagnosis</subject><subject>Lupus Nephritis - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>nephritis</subject><subject>prospective</subject><subject>Prospective Studies</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>study</subject><subject>systemic</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVUt2qEzEQXkQ51qOPIAQR0YvW7CbZ7CoKUqrnQMEL9TrMZqfdlOzPSbLndO98BF_CF_NJTGkpeiXmZhi-b76ZyTdJ8iylizS-17tFynIxzzJeLtKyZItQ0ZzHuL-XzM7Q_WRGKS3nZUr5w-SR97uY5nmeXSQXBYsEms2Sn1dm26Aj0AXz6_uPBgdw0BE_2qGBgMQh6GBuTZhIPTrTbYmffMDWaGLHYfQE3RQabCH0PmYvv6xXr0htPIJHgnvQ6CoIpu88uTOhiXodWNJCZzbowxF5S4DYPkoHdC0ZXO8HPDTFOBXYyRv_OHmwAevxySleJt8-rr4ur-brz5-ulx_Wcy2Y4HPQmSy0lJJnjIGuippzKUCCyDnLsSxLipuKVoxSXeQ1sKqWksm6zCgKwRi7TN4fdYexarHW2AUHVg3OtOAm1YNRfyOdadS2v1WpELGTjAIvTgKuvxnjhqo1XqO10GE_eiVFwQSVxT-JaZ6XjEkeiW-ORB3_xTvcnKdJqTpcg9qpg-XqYLk6XIM6XYPax-Knf-5zLj3ZH_HnJxy8BruJ1mvjzzRe5JIWNNLeHWl3xuL0HwOo5eqacfYbvlXX7w</recordid><startdate>199307</startdate><enddate>199307</enddate><creator>KRAMERS, C.</creator><creator>TERMAAT, R. M.</creator><creator>BORG, E. J.</creator><creator>BRUGGEN, M. C. J.</creator><creator>KALLENBERG, C. G. M.</creator><creator>BERDEN, J. H. M.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199307</creationdate><title>Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis</title><author>KRAMERS, C. ; TERMAAT, R. M. ; BORG, E. J. ; BRUGGEN, M. C. J. ; KALLENBERG, C. G. M. ; BERDEN, J. H. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5354-ac278c7774233acb8d4475a7a56436e9990efb0b300c86da3bd7737d920e55333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>antibodies</topic><topic>Antibodies, Antinuclear - immunology</topic><topic>anti‐DNA</topic><topic>anti‐HS reactivity</topic><topic>Biological and medical sciences</topic><topic>Cross Reactions - immunology</topic><topic>cross‐reactivity</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>erythematosus</topic><topic>Female</topic><topic>Heparitin Sulfate - immunology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Longitudinal Studies</topic><topic>lupus</topic><topic>Lupus Erythematosus, Systemic - diagnosis</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Lupus Nephritis - diagnosis</topic><topic>Lupus Nephritis - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>nephritis</topic><topic>prospective</topic><topic>Prospective Studies</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>study</topic><topic>systemic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KRAMERS, C.</creatorcontrib><creatorcontrib>TERMAAT, R. M.</creatorcontrib><creatorcontrib>BORG, E. J.</creatorcontrib><creatorcontrib>BRUGGEN, M. C. J.</creatorcontrib><creatorcontrib>KALLENBERG, C. G. M.</creatorcontrib><creatorcontrib>BERDEN, J. H. M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KRAMERS, C.</au><au>TERMAAT, R. M.</au><au>BORG, E. J.</au><au>BRUGGEN, M. C. J.</au><au>KALLENBERG, C. G. M.</au><au>BERDEN, J. H. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>1993-07</date><risdate>1993</risdate><volume>93</volume><issue>1</issue><spage>34</spage><epage>38</epage><pages>34-38</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><coden>CEXIAL</coden><abstract>SUMMARY
Cross‐reactive antibodies against heparan sulphate (HS) have been suggested to play a role in initiating renal disease in SLE. Recently, we found that HS‐reactivity is mediated by anti‐DNA antibodies complexed with DNA and histones. To evaluate the clinical significance of anti‐HS reactivity, we studied prospectively a cohort of 72 consecutive SLE patients, of whom 22 experienced 40 exacerbations. In 20 of these exacerbations renal symptoms were present. In these 20 exacerbations significantly higher anti‐DNA (median 1:160) and anti‐HS (median 1:30) titres were detected compared with exacerbations without renal manifestations (median 1:60 for anti‐DNA and negative for anti‐HS). There were no correlations with other symptoms of SLE. Anti‐HS titres showed a significant correlation with anti‐DNA antibody titres (rs= 0·57, P < 0·05). Anti‐HS without anti‐DNA reactivity was never detected. Some SLE patients showed a high anti‐DNA titre without anti‐HS reactivity, suggesting that not all anti‐DNA antibodies are able to bind to histone/DNA complexes and thus to exhibit anti‐HS reactivity. Our findings indicate that anti‐HS reactivity is correlated with renal disease in SLE.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>8324902</pmid><doi>10.1111/j.1365-2249.1993.tb06493.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9104 |
| ispartof | Clinical and experimental immunology, 1993-07, Vol.93 (1), p.34-38 |
| issn | 0009-9104 1365-2249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1554757 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | antibodies Antibodies, Antinuclear - immunology anti‐DNA anti‐HS reactivity Biological and medical sciences Cross Reactions - immunology cross‐reactivity Enzyme-Linked Immunosorbent Assay erythematosus Female Heparitin Sulfate - immunology Humans Incidence Longitudinal Studies lupus Lupus Erythematosus, Systemic - diagnosis Lupus Erythematosus, Systemic - immunology Lupus Nephritis - diagnosis Lupus Nephritis - immunology Male Medical sciences nephritis prospective Prospective Studies Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis study systemic |
| title | Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A50%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Higher%20anti%E2%80%90heparan%20sulphate%20reactivity%20during%20systemic%20lupus%20erythematosus%20(SLE)%20disease%20exacerbations%20with%20renal%20manifestations;%20a%20long%20term%20prospective%20analysis&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=KRAMERS,%20C.&rft.date=1993-07&rft.volume=93&rft.issue=1&rft.spage=34&rft.epage=38&rft.pages=34-38&rft.issn=0009-9104&rft.eissn=1365-2249&rft.coden=CEXIAL&rft_id=info:doi/10.1111/j.1365-2249.1993.tb06493.x&rft_dat=%3Cproquest_pubme%3E16693374%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16693374&rft_id=info:pmid/8324902&rfr_iscdi=true |